Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
quilizumab
- Development stage
- Phase 2
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
Quilizumab is a humanized IgG1 monoclonal antibody developed for the treatment of allergic diseases such as asthma, allergic rhinitis, and chronic urticaria. It specifically targets the M1-prime segment of membrane-bound immunoglobulin E (IgE), which is present on IgE-switched B cells and memory B cells but not on soluble IgE in serum. By binding to this segment, quilizumab depletes these B cell populations through apoptosis and antibody-dependent cell-mediated cytotoxicity, leading to reduced production of soluble IgE and dampening the effector cell response to allergens. Quilizumab was developed by Genentech and reached phase 2 clinical trials for several allergic conditions before development was discontinued[2][3][4][7].
- Other names
- Anti M1 prime monoclonal antibody
02
Targets
mIgE (Membrane-bound immunoglobulin E)
Beyond the preview
Go deeper on quilizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on quilizumab.